Mild bronchial asthma: a modern treatment concept
https://doi.org/10.21518/2079-701X-2019-15-29-36
Abstract
Mild bronchial asthma (BA) occurs in 50–75% of patients with this disease. It is characterized by clinical symptoms that are controlled by low doses of inhaled glucocorticoids (IGCS) or anti-leukotriene drugs. Mild BA reduces the quality of life of patients, is accompanied by the development of severe, in some cases fatal exacerbations, and is characterized by a significant cost of treatment. One of the main problems in the management of patients with this disease is their low adherence to IGCS treatment and the excessive use of short-acting 2-adrenomimetic agents. Several clinical studies have shown that the use of a combination of budesonide/formoterol (Symbicort® Turbuhaler®) in an «as needed» mode reduces the incidence of severe exacerbations of mild BA as well as low doses of budesonide, and is characterized by a lower cumulative dose of this glucocorticoid. The results obtained were the basis for the creation of a new treatment concept, which gives preference to the combination of IGCS / formoterol «as needed» in mild BA as a supporting therapy, and for the management of symptoms of the disease.
About the Authors
A. V. Emel’yanov
North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Dr. of Sci. (Med), Professor, Head of the Department of Pulmonology,
41, Kirochnaya St., St. Petersburg, 191015
E. V. Leshenkova
North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Cand. of Sci. (Med), Associate Professor of the Department of Pulmonology,
41, Kirochnaya St., St. Petersburg, 191015
G. R. Sergeyeva
North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Cand. of Sci. (Med), Associate Professor of the Department of Pulmonology,
41, Kirochnaya St., St. Petersburg, 191015
References
1. Global Asthma Report. 2018. Available at: http://www.globalasthmareport.org/Global Asthma Report 2018.pdf.
2. Federal clinical guidelines for bronchial asthma. 2019. (In Russ.) Available at: http://spulmo.ru/upload/kr_bronhastma_2019.pdf.
3. Global Strategy for Asthma Management and Prevention. Revised 2019. Available at: https://www.ginasthma.org.
4. Dusser D., Montani D., Chanez P., de Blic J., Delacourt C., Deschildre A., Devillier P., Didier A., Leroyer C., Marguet C., Martinat Y., Piquet J., Raherison C., Serrier P., Tillie-Leblond I., Tonnel A.B., Tunon de Lara M., Humbert M. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591-604. doi:10.1111/j.1398-9995.2007.01394.x.
5. Arkhipov V.V., Grigoryeva E.V., Gavrishina E.V. Control of bronchial asthma in Russia: results of NIKA multi-center observational study. Pul'monologiya = Russian Pulmonology. 2011;(6):87-93. (In Russ.) doi: 10.18093/0869- 0189-2011-0-6-87-93.
6. Salmeron S., Liard R., Elkharrat D., Muir J., Neukirch F., Ellrodt A. Asthma severity and adequacy of management in accident and emergency departments in France: a prospective study. Lancet. 2001;358(9282):629-635. doi: 10.1016/s0140-6736(01)05779-8.
7. Chapman K.R., Impact of ‘mild’ asthma on health outcomes: findings of a systematic search of the literature. Respir Med. 2005;99(11):1350-1362. doi: 10.1016/j.rmed.2005.03.020.
8. O’Byrne P.M., Pedersen S., Lamm C.J., Tan W.C., Busse W.W.; START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009;179(1):19-24. doi: 10.1164/rccm.200807-1126OC.
9. Guilbert T.W., Garris C., Jhingran P., Bonafede M., Tomaszewski K.J., Bonus T., Hahn R.M., Schatz M. Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life. J Asthma. 2011;48(2):126-132. doi: 10.3109/02770903.2010.535879.
10. Djukanović R., Wilson J.W., Britten K.M., Wilson S.J., Walls A.F., Roche W.R., Holgate S.T. Effect of an Inhaled Corticosteroid on Airway Inflammation and Symptoms in Asthma. Am Rev Respir Dis. 1992;145(3):669-674. doi: 10.1164/ajrccm/145.3.669.
11. Boulay M.E., Boulet L.P. Discordance between asthma control clinical, physiological and inflammatory parameters in mild asthma. Respir Med. 2013;107(4):511-518. doi: 10.1016/j.rmed.2012.12.015.
12. Harrison B., Stephenson P., Mohan G., Nasser S. An ongoing Confidential Enquiry into asthma deaths in the Eastern Region of the UK, 2001–2003. Prim Care Respir J. 2005;14(6):303- 313. doi: 10.1016/j.pcrj.2005.08.004.
13. Fletcher H.J., Ibrahim S.A., Speight N. Survey of asthma deaths in the Northern region, 1970– 85. Arch Dis Child. 1990;65(2):163-167. doi: 10.1136/adc.65.2.163.
14. Sturdy P.M., Butland B.K., Anderson H.R. Ayres J.G., Bland J.M., Harrison B.D.W., Peckitt C., Victor C.R. Deaths certified as asthma and use of medical services: a national case–control study. Thorax. 2005;60(11):909-915. doi: 10.1136/thx.2004.025593.
15. The National Review of Asthma Deaths, Why Asthma Still Kills, 2014. Available at: https://www.rcplondon.ac.uk/projects/outputs/whyasthma-still-kills.
16. Olaguibel J., Quirce S., Juliá B., Fernández C., Fortuna A., Molina J.; MAGIC Study Group. Measurement of asthma control according to global initiative for asthma guidelines: a comparison with the asthma control questionnaire. Respir Res. 2012;13:50. doi: 10.1186/1465-9921-13-50.
17. Price D., Fletcher M., van der Molen T. Asthma control and management in 8,000 European patients: the REcognise asthma and LInk to symptoms and experience (REALISE) survey. NPJ Prim Care Respir Med. 201;24:14009. doi: 10.1038/npjpcrm.2014.9.
18. Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patientreported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012;21(123):66-74. doi: 10.1183/09059180.00008111.
19. Partridge M.R., van der Molen T., Myrseth S.E., Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. doi: 10.1186/1471-2466-6-13.
20. International Primary Care Respiratory Group, Asthma Control Tools: Users’ Guide, 2016. Available at: www.theipcrg.org/display/TreatP/Asthma+Control+Tools%3A+Users %27+ Guide.
21. Kocks J.W.H., Seys S.F., van Duin T.S., Diamant Z., Tsiligianni I.G. Assessing patient-reported outcomes in asthma and COPD patients: which can be recommended in clinical practice? Curr Opin Pulm Med. 2018;24(1):18-23. doi: 10.1097/MCP.0000000000000447.
22. O’Byrne P.M., Jenkins C., Bateman E.D. The paradoxes of asthma management: time for a new approach? Eur Respir J. 2017;50(3). pii: 1701103. doi: 10.1183/13993003.01103-2017.
23. Stanford R.H., Shah M.B., D’Souza A.O., Dhamane A.D., Schatz M. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403-407. doi: 10.1016/j.anai.2012.08.014.
24. Anderson H.R., Ayres J.G., Sturdy P.M., Bland J.M., Butland B.K., Peckitt C., Victor C.R. Bronchodilator treatment and deaths from asthma: case-control study. BMJ. 2005;330(7483):117. doi:10.1136/bmj.38316.729907.8F.
25. Reddel H.K., Busse W.W., Pedersen S., Tan W.C., Chen Y.-Z., Jorup C., O’Byrne P.M. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017;389(10065):157-166. doi: 10.1016/ S0140-6736(16)31399-X.
26. Pauwels R.A., Pedersen S., Busse W.W., Tan W.C., Chen Y.Z., Ohlsson S.V., Ullman A., Lamm C.J., O’Byrne P.M.; START Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomised, doubleblind trial. Lancet. 2003;361(9363):1071-1076. doi: 10.1016/S0140-6736(03)12891-7.
27. O’Byrne P.M., Barnes P.J., Rodriguez-Roisin R., Runnerstrom E., Sandstrom T., Svensson K., Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1392-1397. doi: 10.1164/ajrccm.164.8.2104102.
28. O’Byrne P.M., Pedersen S., Lamm C.J., Tan W.C., Busse W.W., START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009;179(1):19-24. doi: 10.1164/rccm.200807-1126OC.
29. Nathan R.A., Thompson P.J., Price D., Fabbri L.M., Salvi S., Gonzalez-Diaz S., Maspero J.F., MorenoCantu J.J., Fish J.E., Murphy K. Taking aim at asthma around the world: global results of the asthma insight and management survey in the Asia-Pacific region, Latin America, Europe, Canada, and the United States. J Allergy Clin Immunol Pract. 2015;3(5):734-742.e5. doi: 10.1016/j.jaip.2015.04.013.
30. Plakas S., Mastrogiannis D., Mantzorou M., Adamakidou T., Fouka G., Bouziou A., Tsiou C., Morisky D. Validation of the 8-item Morisky medication adherence scale in chronically ill ambulatory patients in rural Greece. Open J. Nurs. 2016;6(3):158–169. doi: 10.4236/ojn.2016.63017.
31. Bender B.G., Rankin A., Tran Z.V., Wamboldt F.S. Brief-interval telephone surveys of medication adherence and asthma symptoms in the Childhood Asthma Management Program Continuation Study. Ann Allergy Asthma Immunol. 2008;101(4):382-386. doi: 10.1016/ S1081-1206(10)60314-6.
32. Irwin R.S., Richardson N.D. Side effects with inhaled corticosteroids. Chest. 2006;130(1 Suppl):41S-53S. doi: 1378/chest.130.1_suppl.41S.
33. Papi A., Canonica G.W., Maestrelli P., Paggiaro P., Olivieri D., Pozzi E. Crimi N., Vignola A.M., Morelli P., Nicolini G., Fabbri L.M.; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356(20):2040-2052. doi: 10.1056/NEJMoa063861.
34. O’Byrne P.M., FitzGerald J.M., Bateman E.D., Barnes P.J., Zhong N., Keen C., Jorup C., Lamarca R., Ivanov S., Reddel H.K. Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma. N Engl J Med. 2018;378(20):1865-1876. doi: 10.1056/NEJMoa1715274.
35. Bateman E.D., Reddel H.K., O’Byrne P.M., Barnes P.J., Zhong N., Keen C., Jorup C., Lamarca R., Siwek-Posluszna A., FitzGerald J.M. As-Needed Budesonide–Formoterol versus maintenance Budesonide in Mild asthma. N Engl J Med. 2018;378(20):1877-1887. doi: 10.1056/NEJMoa1715275.
36. Beasley R., Holliday M., Reddel H.K., Braithwaite I., Ebmeier S., Hancox R.J., Harrison T., Houghton C., Oldfield K., Papi A., Pavord I.D., Williams M., Weatherall M.; Novel START Study Team. Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma. N Engl J Med. 2019;380(21):2020- 2030. doi: 10.1056/NEJMoa1901963.
37. Bousquet J., van Cauwenberge P., Khaltaev N. (eds). Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8- 160. doi: 10.1111/j.1398-9995.2007.01620.x.
38. Wang L., Yin J., Fadel R., Montagut A., de Beaumont O., Devillier P. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy. 2014;69(9):1181-1188. doi: 10.1111/all.12188.
39. Virchow C., Backer V., Kuna P. Prieto L., Nolte H., Villesen H.H., Ljørring C., Riis B., de Blay F. Efficacy of house dust mite allergen sublingual immunotherapy tablets in adults patients with allergic asthma. A randomized clinical trial. JAMA. 2016;315(16):1715-1725. doi: 10.1001/jama.2016.3964.
40. Lee J., McDonald C. Review: Immunotherapy improves some symptoms and reduces longterm medication use in mild to moderate asthma. Ann Intern Med. 2018;169(4):JC17. doi: 10.7326/ACPJC-2018-169-4-017.
41. S.N. Avdeev, Z.R. Aisanov, V.V. Arkhipov, A.S. Belevskiy, A.A. Vizel, I.V. Demko, A.V. Emelianov, N.I. Ilina, O.M. Kurbacheva, I.V. Leschenko, N.M. Nenasheva, S.I. Ovcharenko, and R.S. Fassakhov on behalf of expert group. The Principles of the Treatment of Mild Asthma: Consistent Guidelines of the Russian Association of Allergology and Clinical Immunology and the Russian Respiratory Society. Prakticheskaya pul'monologiya = Practical Pulmonology. 2017;(1):44-54. (In Russ.) Available at: http:// www.atmosphere-ph.ru/modules/Magazines/articles/pulmo/pp_1_2017_82.pdf.
42. The Register of Medicinal Products. (In Russ.) Available at: http://grls.rosminzdrav.ru/
Review
For citations:
Emel’yanov AV, Leshenkova EV, Sergeyeva GR. Mild bronchial asthma: a modern treatment concept. Meditsinskiy sovet = Medical Council. 2019;(15):29-36. (In Russ.) https://doi.org/10.21518/2079-701X-2019-15-29-36
Views:
772
Email this article 